Session

UEG Research Prize 2020 Session

OZANIMOD AS INDUCTION THERAPY IN MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY
OZANIMOD AS INDUCTION THERAPY IN MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

UEG Research Prize 2020 Session  et al.

ETROLIZUMAB VERSUS INFLIXIMAB FOR TREATING PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 GARDENIA STUDY
ETROLIZUMAB VERSUS INFLIXIMAB FOR TREATING PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 GARDENIA STUDY

UEG Research Prize 2020 Session  et al.

UEG Research Prize 2020: Therapeutic mechanisms of controlled-ileocolonic-release nicotinamide (CICR-NAM) in IBD
UEG Research Prize 2020: Therapeutic mechanisms of controlled-ileocolonic-release nicotinamide (CICR-NAM) in IBD

UEG Research Prize 2020 Session

Item 1 - 3 / 3
1